Patents Assigned to Human Genome Sciences, Inc.
-
Publication number: 20130108606Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: October 16, 2012Publication date: May 2, 2013Applicant: Human Genome Sciences, Inc.Inventor: Human Genome Sciences, Inc.
-
Patent number: 8410248Abstract: The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating diseases, disorders, and/or conditions (such as immune, cardiovascular, cancer, and other proliferative diseases, disorders, and/or conditions) related to said human secreted proteins. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.Type: GrantFiled: April 2, 2010Date of Patent: April 2, 2013Assignee: Human Genome Sciences Inc.Inventors: Craig A. Rosen, Steven M. Ruben
-
Patent number: 8372948Abstract: The present invention relates to 12 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.Type: GrantFiled: November 3, 2008Date of Patent: February 12, 2013Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Paul E. Young, Joseph J. Kenny, Henrik S. Olsen, Paul A. Moore, Ying-Fei Wei, John M. Greene, Steven M. Ruben, Ding Liu, Paul R. Crocker
-
Patent number: 8334365Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: June 7, 2007Date of Patent: December 18, 2012Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, David W. LaFleur
-
Patent number: 8329179Abstract: The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists and/or antagonists of DR4 activity.Type: GrantFiled: January 18, 2008Date of Patent: December 11, 2012Assignees: Human Genome Sciences, Inc., The Regents of the University of MichiganInventors: Jian Ni, Craig A. Rosen, James G. Pan, Reiner L. Gentz, Vishva M. Dixit
-
Patent number: 8303951Abstract: The present invention relates to a Neutrokine-alpha antibody and a process for producing a Neutrokine-alpha antibody. The invention further relates to screening methods for identifying compounds that inhibit or enhance the action of Neutrokine-alpha. Also provided are diagnostic methods for detecting autoimmune disorders and therapeutic methods for treating autoimmune disorders using a Neutrokine-alpha antibody.Type: GrantFiled: February 26, 2009Date of Patent: November 6, 2012Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni
-
Patent number: 8287859Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: June 3, 2010Date of Patent: October 16, 2012Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, David LaFleur
-
Patent number: 8268979Abstract: A human mutY polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for preventing and/or treating diseases associated with a mutation in this gene. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, are also disclosed.Type: GrantFiled: March 10, 2011Date of Patent: September 18, 2012Assignee: Human Genome Sciences, Inc.Inventor: Ying-Fei Wei
-
Patent number: 8252739Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: April 1, 2011Date of Patent: August 28, 2012Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
-
Publication number: 20120213777Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: ApplicationFiled: April 30, 2012Publication date: August 23, 2012Applicant: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Vivian R. Albert, Steven M. Ruben, Ruth E. Wager
-
Patent number: 8231873Abstract: The present invention relates to a Neutrokine-alpha antibody and a process for producing a Neutrokine-alpha antibody. The invention further relates to screening methods for identifying compounds that inhibit or enhance the action of Neutrokine-alpha. Also provided are diagnostic methods for detecting autoimmune disorders and therapeutic methods for treating autoimmune disorders using a Neutrokine-alpha antibody.Type: GrantFiled: August 27, 2010Date of Patent: July 31, 2012Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni
-
Patent number: 8216569Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: GrantFiled: October 31, 2007Date of Patent: July 10, 2012Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Vivian R. Albert, Steven M. Ruben, Ruth E. Wager
-
Patent number: 8212004Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.Type: GrantFiled: February 10, 2005Date of Patent: July 3, 2012Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni
-
Patent number: 8211439Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: October 30, 2007Date of Patent: July 3, 2012Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Steven M. Ruben, Olivier Blondel
-
Patent number: 8211649Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.Type: GrantFiled: March 30, 2007Date of Patent: July 3, 2012Assignees: Human Genome Sciences, Inc., Board of Regents, The University of Texas SystemInventors: Thi-Sau Migone, Jerry L. Klein, Yasuhiro Oki, Anas Younes
-
Patent number: 8206708Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: GrantFiled: April 28, 2011Date of Patent: June 26, 2012Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Vivian R. Albert, Steven M. Ruben, Ruth E. Wager
-
Publication number: 20120122762Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.Type: ApplicationFiled: January 26, 2012Publication date: May 17, 2012Applicant: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, Craig A. Rosen, Daniel R. Soppet, Kenneth C. Carter, Daniel P. Bednarik, Gregory A. Endress, Guo-Liang Yu, Jian Ni, Ping Feng, Paul E. Young, John M. Greene, Ann M. Ferrie, D. Roxanne Duan, Jing-Shan Hu, Kimberly A. Florence, Henrik S. Olsen, Carrie L. Fischer, Reinhard Ebner, Laurie A. Brewer, Paul A. Moore, Yanggu Shi, David W. LaFleur, Yi Li, Zhizhen Zeng, Hla Kyaw
-
Publication number: 20120121606Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.Type: ApplicationFiled: January 23, 2012Publication date: May 17, 2012Applicant: HUMAN GENOME SCIENCES, INC.Inventors: Steven M. Ruben, Steven C. Barash, Gil H. Choi, Tristan Vaughan, David Hilbert
-
Patent number: 8173122Abstract: The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokine-alpha and/or Neutrokine-alphaSV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.Type: GrantFiled: July 9, 2008Date of Patent: May 8, 2012Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni
-
Patent number: 8168205Abstract: The present invention provides polynucleotide sequences of the genome of Streptococcus pneumoniae, polypeptide sequences encoded by the polynucleotide sequences, corresponding polynucleotides and polypeptides, vectors and hosts comprising the polynucleotides, and assays and other uses thereof. The present invention further provides polynucleotide and polypeptide sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use.Type: GrantFiled: December 11, 2009Date of Patent: May 1, 2012Assignee: Human Genome Sciences, Inc.Inventors: Charles A. Kunsch, Gil H. Choi, Patrick J. Dillon, Craig A. Rosen, Steven C. Barash, Michael R. Fannon, Brian A. Dougherty